New oral medications for acute migraine — one pending launch and two more that could be approved in the coming months — likely won’t shake up formulary coverage for a condition that’s largely treated by generic triptan medications, pharmacy benefit experts say.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.